PET scan could personalize breast cancer treatment after drug failure

NCT ID NCT06595563

Recruiting now Disease control Sponsor: Jules Bordet Institute Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 23, 2026 · Updated 30 times

Summary

This study is for people with advanced HER2-positive breast cancer whose disease has worsened after treatment with trastuzumab deruxtecan (T-DXd). Researchers will use a special PET scan (HER2-PET/CT) to see if the cancer still has HER2 targets. If the scan is positive, participants get a different drug (T-DM1); if negative, they receive standard care. The goal is to see if the scan can help choose the next best treatment and improve outcomes.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HER2-POSITIVE METASTATIC BREAST CANCER are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Institut Jules Bordet
RECRUITING

Anderlecht, Brussels Capital, 1070, Belgium

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

HER2-POSITIVE ADVANCED BREAST CANCER HER2-POSITIVE METASTATIC BREAST CANCER